Skip to main content
. 2022 Jul 26;12(10):2454–2473. doi: 10.1158/2159-8290.CD-21-1690

Figure 1.

Figure 1. Nonmyelinating SC signature scores correlate with diminished survival in patients with pancreatic adenocarcinoma and with pathways related to cancer invasion. A, Hierarchical organization of SCs from Tabula-Sapiens (full lines) with dashed arrows indicating transitions in the SC lineage (22). B, Forest plot with hazard ratio and 95% CI. C–F, Kaplan–Meier curves of overall survival (C, E) and PFS (D, F) with high or low scores for signatures of nonmyelinating SC (C, D), and myelinating SC (E, F) in 178 TCGA PAAD patients. G, Nonmyelinating and myelinating SC signature scores in PDAC subtypes (S: squamous, P: progenitor, I: immunogenic, A: ADEX). H and I, Heatmap of gene sets correlating with high and low scores for nonmyelinating SC signature (H) and myelinating SC signature (I) in TCGA PAAD patients. Columns represent TCGA PAAD samples that have been rank ordered by the top row signature. Arrows indicate survival cutoff used in B and D with low survival patients at the left of the arrow. J, Top 7 enriched pathways in HEI-286 cocultured with MiaPaCa-2 as compared with HEI-286 SCs alone (EnrichR, human KEGG 2019 data set). K, Kaplan–Meier curve of overall survival with high or low scores for the cancer-exposed HEI-286 SC (HEI-mix) signature in 178 TCGA PAAD patients. L, Heatmap of gene sets correlating with high and low scores for cancer-exposed HEI-286 SC (HEI-mix) signature in TCGA PAAD patients. Columns represent TCGA PAAD samples that have been rank ordered by the top row signature. M, Kaplan–Meier of overall survival of PDAC patients with high or low GFAP expression in SCs determined histologically.

Nonmyelinating SC signature scores correlate with diminished survival in patients with pancreatic adenocarcinoma and with pathways related to cancer invasion. A, Hierarchical organization of SCs from Tabula Sapiens (full lines), with dashed arrows indicating transitions in the SC lineage (22). B, Forest plot with hazard ratio and 95% confidence interval. ADEX, aberrantly differentiated endocrine exocrine. C–F, Kaplan–Meier curves of overall survival (C, E) and progression-free survival (PFS; D, F) with high or low scores for signatures of nonmyelinating SCs (C, D) and myelinating SCs (E, F) in 178 TCGA pancreatic adenocarcinoma (PAAD) patients. NS, not signficant. G, Nonmyelinating and myelinating SC signature scores in PDAC subtypes (A, ADEX; I, immunogenic; P, progenitor; S, squamous). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. H, Heat map of gene sets correlating with high and low scores for nonmyelinating SC signature in TCGA PAAD patients. I, Heat map of gene sets correlating with high and low scores for myelinating SC signature in TCGA PAAD patients. Columns represent TCGA PAAD samples that have been rank ordered by the top row signature. ECM, extracellular matrix; HMDB, Human Metabolic Database; KEGG, Kyoto Encyclopedia of Genes and Genomes; SMPDB, Small Molecule Pathway Database. J, Top seven enriched pathways in HEI-286 cocultured with MiaPaCa-2 as compared with HEI-286 SCs alone (EnrichR, human KEGG 2019 data set). K, Kaplan–Meier curve of overall survival with high or low scores for the cancer-exposed HEI-286 SC (HEI-mix) signature in 178 TCGA PAAD patients. L, Heat map of gene sets correlating with high and low scores for cancer-exposed HEI-286 SC (HEI-mix) signature in TCGA PAAD patients. Columns represent TCGA PAAD samples that have been rank ordered by the top row signature. M, Kaplan–Meier of overall survival of PDAC patients with high or low GFAP expression in SCs determined histologically.